Which Pulmonx RSU grants were connected to the June 1, 2026 insider share sales?

The tax-cover sales were linked to Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026. Each footnote ties a portion of the 14,594 shares sold to tax withholding obligations for RSUs from one of these specific grant dates.

Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pulmonx Corp General Counsel David Aaron Lehman reported the sale of a total of 14,594 shares of Pulmonx common stock on June 1, 2026 at a price of $1.54 per share, executed in four separate transactions. According to the footnotes, all of these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026, making the activity compensation- and tax-related rather than a discretionary reduction of his investment position.

Insider Trade Summary

Net Seller: 14,594 shares ($22,475)

Net Sell 4 txns

Insider Lehman David Aaron

Role GENERAL COUNSEL

Sold 14,594 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,876	$1.54	$6K
Sale	Common Stock	2,264	$1.54	$3K
Sale	Common Stock	3,539	$1.54	$5K
Sale	Common Stock	4,915	$1.54	$8K

Holdings After Transaction: Common Stock — 386,879 shares (Direct, null)

Footnotes (1)

These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.

Key Figures

Total shares sold: 14,594 shares Sale price: $1.54 per share First RSU grant date: March 1, 2023 +3 more

6 metrics

Total shares sold 14,594 shares Aggregate insider sales on June 1, 2026

Sale price $1.54 per share Price for all four reported transactions

First RSU grant date March 1, 2023 RSUs whose vesting triggered part of the tax-cover sale

Second RSU grant date March 1, 2024 RSUs whose vesting triggered part of the tax-cover sale

Third RSU grant date March 3, 2025 RSUs whose vesting triggered part of the tax-cover sale

Fourth RSU grant date March 2, 2026 RSUs whose vesting triggered part of the tax-cover sale

Key Terms

Restricted Stock Units, tax withholding obligations, open-market sale, Common Stock

4 terms

Restricted Stock Units financial

"in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lehman David Aaron

(Last)

(First)

(Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	GENERAL COUNSEL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		3,876	D	$1.54	386,879	D
Common Stock	06/01/2026		S⁽²⁾		2,264	D	$1.54	384,615	D
Common Stock	06/01/2026		S⁽³⁾		3,539	D	$1.54	381,076	D
Common Stock	06/01/2026		S⁽⁴⁾		4,915	D	$1.54	376,161	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.

	/s/ David Aaron Lehman	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pulmonx (LUNG) report for David Aaron Lehman?

Pulmonx reported that General Counsel David Aaron Lehman sold 14,594 shares of common stock. The sales occurred in four separate transactions on June 1, 2026 at $1.54 per share, tied to tax withholding from vesting Restricted Stock Units rather than discretionary open-market selling.

How many Pulmonx (LUNG) shares did the General Counsel sell and at what price?

David Aaron Lehman sold a total of 14,594 Pulmonx common shares at $1.54 per share. These sales were split into four reported transactions, all executed on June 1, 2026, and were specifically designated to satisfy tax withholding obligations from RSU vesting events.

Why did Pulmonx’s General Counsel sell 14,594 LUNG shares?

The filing states the shares were sold to cover tax withholding obligations from vesting Restricted Stock Units. Footnotes explain that each sale related to RSUs granted in 2023, 2024, 2025, and 2026, indicating the transactions were driven by compensation-related tax needs, not a change in investment view.

Were Pulmonx (LUNG) insider sales by David Aaron Lehman open-market trades?

The transactions are coded as open-market sales at $1.54 per share, but footnotes clarify the purpose. All shares sold on June 1, 2026 were to meet tax withholding obligations tied to RSU vesting, so they function as mandatory tax-related dispositions rather than purely discretionary trading activity.